A Phase 1/2 interventional study of vesemnogene lantuparvovec in Spinal Muscular Atrophy, sponsored by Lantu Biopharma. Active, not recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by Lantu Biopharma · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Muscular Atrophy, Spinal with a site in China — 6 open to participants now, 13 under way, 4 of them phase 3. Muscular Atrophy, Spinal · China.
Among the 23 studies in Muscular Atrophy, Spinal with a site in China, this one is the 11th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2024, is one of 2 in phase 1/2, reaches primary completion later than 5 of the 12 other live ones, and was the 15th registered.
282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.
Browse Muscular Atrophy, Spinal studies →6 of the 23 studies in Muscular Atrophy, Spinal with a site in China are open now. Recruiting first, the newest first:
Biogen · Sites in China, United States, Brazil and 2 more countries
Ages 15–60
Biogen · Sites in China, United States, Australia and 4 more countries
Ages 0 days–42 days
GeneCradle Inc · Sites in China
Ages 0 mo–6 mo
Wan-Jin Chen · Sites in China
Ages 1 wk–70 yrs · Healthy volunteers
Hangzhou Jiayin Biotech Ltd · Sites in China
Ages 1 days–2 yrs
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 7
First in 2016; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 20 is below the median of 29 across 156 interventional studies indexed under Muscular Atrophy, Spinal.
Median enrollment 35 across the 16 interventional studies, 200 across the 7 observational. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 23 have an industry lead sponsor. The 10 most frequent:
Lantu Biopharma is the lead sponsor of 3 studies on the registry; none are open to participants now.
Lantu Biopharma has 2 studies filed under Muscular Atrophy, Spinal — fewer than ten, so there is no comparison to draw.
5 of the studies in Muscular Atrophy, Spinal with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06971094Phase 3GeneCradle IncSafety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III | 2026-12-31 |
| NCT05824169GeneCradle IncEvaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients | 2026-12 |
| NCT07822711Peking University Third HospitalEffects of Different Stiffness Settings During Robotic Isokinetic Training in Children With SMA | 2027-01-15 |
| NCT05042921BiogenPediatric Spinal Muscular Atrophy (SMA) China Registry | 2027-09-02 |
| NCT06288230Lantu BiopharmaAn Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy | 2027-10-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 23 studies in Muscular Atrophy, Spinal with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an interventional study to evaluate safety and efficacy of AAV-hSMN1 in spinal muscular atrophy patients.
Study duration per participant is approximately 25 months including an approximately 30-day screening/baseline period, an approximately 24-month study observation period including 1 treatment day, and an approximately 24-month follow-up period. Patients will be stratified in two groups, those \< 24 months of age at time of dosing and those ≥ 24 months of age at time of dosing. This study will be conducted in 2 stages:
Stage 1: dose escalting study in children \<24 months of age. Stage 2: the selecetd dose from Stage 1 in children ≥ 24 months of age.
Patients will be tested at baseline and return for follow-up visits twice a week through the first month post dose, and followed by visits at months 2, 3, 6 12, 18 and 24 post infusion. Unscheduled visits may occur if the investigator determines that they are necessary.
For patients enrolled from overseas, follow-up visits with patient's own paediatrician together with remote virtual visits are allowed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose escalting study: Administration Dose A of Vesemnogene Lantuparvovec in children \< 24 months of age
Biological: vesemnogene lantuparvovec
Dose escalting study: Administration Dose B of Vesemnogene Lantuparvovec in children \< 24 months of age
Biological: vesemnogene lantuparvovec
Administration the selected dose of Vesemnogene Lantuparvovec in children ≥ 24 months of age
Biological: vesemnogene lantuparvovec
Exploratory study evaluating the safety and efficacy of vesemnogene lantuparvovec in patients with SMA.
Also known as: AAV-hSMN1
Numbers of participants with adverse events (AEs), serious adverse events (SAEs)
Participants are monitored for safety from baseline up to the end of the follow-up period.
Time frame: Baseline up to 24 months
Change from baseline in developmental gross motor milestones achieved according to WHO criteria
For patients with SMA, the percentage of participants who are able to preserve ambulatory function.
Time frame: Baseline up to 24 months
Change from baseline in CHOP-INTEND in children <24 months of age
The CHOP-INTEND contains 16 items rated from 0 to 4. Total scores range from 0-64. Higher scores indicate higher levels of motor ability.
Time frame: Baseline up to 24 months
Change from baseline in Hammersmith Functional Motor Scale - Expanded (HFMSE) in children ≥ 24 months of age
The HFMSE contains 33 items rated from 0 (unable to perform) to 2 (performs without modification/adaptation/compensation). Total scores range from 0-66. Higher scores indicate higher levels of motor ability.
Time frame: Baseline up to 24 months
Started Oct 2024 (actual). Primary completion is estimated for Oct 2027, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lantu Biopharma